BackAquaBounty Technologies Overview

AquaBounty Technologies Accounts Payable

Latest accounts payable for AQB: $520M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$523.78M
15687.35% YoYΔ $520.46M vs prior year quarter

Peer trimmed avg / median

Loading

AquaBounty Technologies Accounts Payable History

Loading

AquaBounty Technologies vs. peers: Accounts Payable Comparison

Loading

AquaBounty Technologies Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

AquaBounty Technologies (AQB) FAQ

The latest accounts payable for AQB is $520M as of June 2026. That compares with $3.3M in the prior-year period — up 15687.4% year over year. Investors often review this figure alongside AquaBounty Technologies's historical trend and sector peers before judging valuation or financial health.

Over the past year, AQB's accounts payable moved from $3.3M to $520M — a 15687.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AquaBounty Technologies's operating scale or balance-sheet position.

A accounts payable figure of $520M for AQB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting AQB's accounts payable ($520M), review year-over-year change from $3.3M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack AquaBounty Technologies's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.